Characterization of ocular adverse events associated with crizotinib: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase
To evaluate the risk of ocular adverse events (AEs) associated with crizotinib using real-world data from FAERS and VigiBase, and to characterize signal patterns through disproportionality and time-to-onset (TTO) analyses. Reports from FAERS and VigiBase (2011–2025) were analyzed. Disproportionality...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2025-12-01
|
| Серии: | Frontiers in Oncology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1735200/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|